RDC Clinical, Brisbane, 4006, Australia.
School of Medicine, University of Sydney, Sydney, Australia.
Sci Rep. 2021 Mar 24;11(1):6791. doi: 10.1038/s41598-021-86108-2.
To examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. A double-blind, randomised, placebo controlled trial to examine the effect of a Caralluma Fimbriata extract (CFE) on biomarkers of satiety and body composition in overweight adults. Eighty-three men and women aged between 20 and 50 years of age completed 16 weeks of daily supplementation with either CFE or placebo. Plasma cardiometabolic (lipid profile, glucose, insulin) and satiety (ghrelin, leptin, neuropeptideY) biomarkers, body composition, diet history and gastrointenstinal function were assessed at baseline, weeks 4, 8, 12 and 16. Subjects in the CFE and placebo groups were well matched and predominatly female 93% and 87.5%, with a mean age of 40.9 ± 6.7 and 39.5 ± 7.5 years and body mass index (BMI) of 30.0 ± 3.1 and 30.2 ± 2.9 kg/m respectively. There was a significant difference in plasma leptin concentration change between groups at week 16 (p = 0.04), with the placebo group increasing concentration (2.27 ± 4.80 ng/mL) while the CFE group (0.05 ± 4.69 ng/mL) remained the same. At week 16, the CFE group had significantly reduced their calorie intake from baseline compared to the placebo group (245 cal vs 15.8 cal respectively p < 0.01). The CFE group also had a significant reduction in waist circumference of 2.7 cm compared to an increase of 0.3 cm in the placebo group (p = 0.02). A weight increase from baseline was seen in the placebo group that was not observed in the CFE group (1.33 kg weight gain vs 0.37 kg weight loss respectively; p = 0.03). The placebo group also had a significant increase in fat mass, android fat mass, BMI and leptin compared to the CFE group (p = 0.04, 0.02, < 0.01 respectively). CFE was effective at maintaining bodyweight during a non-calorie controlled diet compared to a placebo. The mechanism responsible for this action is requiring further research and could be due to an increase in satiety receptor sensitivity.
评估 Caralluma Fimbriata 提取物(CFE)对超重成年人饱腹感和身体成分生物标志物的影响。
这是一项双盲、随机、安慰剂对照试验,旨在研究 Caralluma Fimbriata 提取物(CFE)对超重成年人饱腹感和身体成分生物标志物的影响。
83 名年龄在 20 至 50 岁之间的男性和女性完成了为期 16 周的每日 CFE 或安慰剂补充。
在基线、第 4、8、12 和 16 周评估了血浆心血管代谢(脂质谱、血糖、胰岛素)和饱腹感(ghrelin、leptin、neuropeptideY)生物标志物、身体成分、饮食史和胃肠道功能。
体重、体脂百分比、腰围、空腹血糖、胰岛素、血脂、ghrelin、leptin 和 Neuropeptide Y。
CFE 和安慰剂组的受试者匹配良好,主要为女性(93%和 87.5%),平均年龄为 40.9±6.7 和 39.5±7.5 岁,体重指数(BMI)分别为 30.0±3.1 和 30.2±2.9kg/m2。第 16 周时,两组间血浆瘦素浓度变化有显著差异(p=0.04),安慰剂组浓度增加(2.27±4.80ng/ml),而 CFE 组(0.05±4.69ng/ml)保持不变。第 16 周时,与安慰剂组相比,CFE 组的卡路里摄入量显著减少(分别为 245 卡路里和 15.8 卡路里,p<0.01)。与安慰剂组腰围增加 0.3cm 相比,CFE 组腰围显著减少 2.7cm(p=0.02)。安慰剂组体重增加,而 CFE 组体重减轻(分别为 1.33kg 体重增加和 0.37kg 体重减轻,p=0.03)。与 CFE 组相比,安慰剂组的体脂百分比、安卓体脂百分比、BMI 和瘦素显著增加(p=0.04、0.02、<0.01)。
与安慰剂相比,CFE 在非热量控制饮食期间维持体重有效。其作用机制需要进一步研究,可能与饱腹感受体敏感性增加有关。